Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)

1412OPHASE II STUDY EVALUATING IMATINIB TO INDUCE PROGRESSION ARREST IN RECIST PROGRESSIVE DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACCEPTABLE FUNCTION LOSS - A STUDY OF THE GERMAN INTERDISCIPLINARY SARCOMA GROUP (GISG)

(2017) B. Kasper et al.   ANNALS OF ONCOLOGY

Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study

(2015) Danique L. M. van Broekhoven et al.   ANNALS OF SURGICAL ONCOLOGY

Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative

(2015) B. Kasper et al.   EUROPEAN JOURNAL OF CANCER

Near universal detection of alterations inCTNNB1and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis

(2015) Aimee M. Crago et al.   GENES CHROMOSOMES & CANCER

‘Difficult to diagnose’ desmoid tumours: a potential role forCTNNB1mutational analysis

(2015) Chiara Colombo et al.   HISTOPATHOLOGY

Prognostic Value of CTNNB1 Gene Mutation in Primary Sporadic Aggressive Fibromatosis

(2014) Danique L. M. van Broekhoven et al.   ANNALS OF SURGICAL ONCOLOGY

CTNNB1 S45F Mutation Predicts Poor Efficacy of Meloxicam Treatment for Desmoid Tumors: A Pilot Study

(2014) Shunsuke Hamada et al.   PLoS One

CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence

(2013) Chiara Colombo et al.   CANCER

 -Catenin Mutation Status and Outcomes in Sporadic Desmoid Tumors

(2013) J. T. Mullen et al.   ONCOLOGIST

β-Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis

(2012) Sebastian Huss et al.   HISTOPATHOLOGY

CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics

(2012) Sophie Le Guellec et al.   MODERN PATHOLOGY

Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis

(2011) M. M. Gounder et al.   CLINICAL CANCER RESEARCH

Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease

(2011) B. Kasper et al.   ONCOLOGIST

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

(2010) N. Penel et al.   ANNALS OF ONCOLOGY

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management

(2010) J Dômont et al.   BRITISH JOURNAL OF CANCER

Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

(2010) R. Chugh et al.   CLINICAL CANCER RESEARCH

Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors

(2008) Alexander J.F. Lazar et al.   AMERICAN JOURNAL OF PATHOLOGY

Difference in characteristics ofAPC mutations between colonic and extracolonic tumors of FAP patients: Variations with phenotype

(2008) Michiko Miyaki et al.   INTERNATIONAL JOURNAL OF CANCER